Stem cells therapy for ALS
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Despite knowledge on the molecular basis of amyotrophic lateral sclerosis (ALS) having quickly progressed over the last few years, such discoveries have not yet translated into new therapeutics. With the advancement of stem cell technologies there is hope for stem cell therapeutics as novel treatments for ALS. AREAS COVERED: We discuss in detail the therapeutic potential of different types of stem cells in preclinical and clinical works. Moreover, we address many open questions in clinical translation. EXPERT OPINION: SC therapy is a potentially promising new treatment for ALS and the need to better understand how to develop cell-based experimental treatments, and how to implement them in clinical trials, becomes more pressing. Mesenchymal stem cells and neural fetal stem cells have emerged as safe and potentially effective cell types, but there is a need to carry out appropriately designed experimental studies to verify their long-term safety and possibly efficacy. Moreover, the cost-benefit analysis of the results must take into account the quality of life of the patients as a major end point. It is our opinion that a multicenter international clinical program aime d at fine-tuning and coordinating transplantation procedures and protocols is mandatory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia
Boillée, S., Yamanaka, K., Lobsiger, C. S., Copeland, N. G., Jenkins, N. A., Kassiotis, G., Kollias, G., & Cleveland, D. W. (2006) · Science · doi:10.1126/science.1123511 · Cited by 1,623
Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications
Wang, Y., Chen, X., Cao, W., & Shi, Y. (2014) · Nature Immunology · doi:10.1038/ni.3002 · Cited by 1,452
Non–cell autonomous toxicity in neurodegenerative disorders: ALS and beyond
Ilieva, H., Polymenidou, M., & Cleveland, D. W. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200908164 · Cited by 1,008 · cited 1×
“However, not only MNs but also astrocytes clearly play a role in ALS pathogenesis [5,17] and the disruption in astrocytic function markedly promotes neurodegeneration.”
BackgroundKang, S. H., Li, Y., Fukaya, M., Lorenzini, I., Cleveland, D. W., Ostrow, L. W., Rothstein, J. D., & Bergles, D. E. (2013) · Nature Neuroscience · doi:10.1038/nn.3357 · Cited by 599 · cited 1×
“However, ALS rodent studies have provided strong evidence that ALS is a non-cell autonomous disease as oligodendroglia may play a significant role in onset and both astroglia and microglia play a role in progression.[4] Deletion of mutant SOD1 in astrocytes and microglia reduced disease severity and boosted the surviv…”
BackgroundLepore, A. C., Rauck, B., Dejea, C., Pardo, A. C., Rao, M. S., Rothstein, J. D., & Maragakis, N. J. (2008) · Nature Neuroscience · doi:10.1038/nn.2210 · Cited by 441
Salminen, A., Ojala, J., Kaarniranta, K., Haapasalo, A., Hiltunen, M., & Soininen, H. (2011) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07738.x · Cited by 333 · cited 3×
“Moreover, recent studies suggest that even during normal aging, astrocytes become less supportive to MNs,[18,19] suggesting also a role of aging in the significant MN death related to astrocytes in a rodent model of familial ALS.”
BackgroundDe Feo, D., Merlini, A., Laterza, C., & Martino, G. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328352ec45 · Cited by 181 · cited 1×
“tion capacity into the damaged brain parenchyma, while also eliciting putative therapeutic effects in different pathological scenarios.[14,53] In these studies, in addition to integration and differentiation into neurons, astrocytes and oligodendrocytes, transplanted NSCs exerted their beneficial effects through an im…”
BackgroundChinta, S. J., Lieu, C. A., DeMaria, M., Laberge, R. ‐., Campisi, J., & Andersen, J. K. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12029 · Cited by 165 · cited 3×
“Moreover, recent studies suggest that even during normal aging, astrocytes become less supportive to MNs,[18,19] suggesting also a role of aging in the significant MN death related to astrocytes in a rodent model of familial ALS.”
Background
Cited by
Functional role of mesenchymal stem cells in the treatment of chronic neurodegenerative diseases
Lo Furno, D., Mannino, G., & Giuffrida, R. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26192 · Cited by 177
Mazzini, L., Gelati, M., Profico, D. C., Sorarù, G., Ferrari, D., Copetti, M., Muzi, G., Ricciolini, C., Carletti, S., Giorgi, C., et al. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0154 · Cited by 128
Self-citationRisk factors and emerging therapies in amyotrophic lateral sclerosis
Nowicka, N., Juranek, J., Juranek, J. K., & Wojtkiewicz, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112616 · Cited by 106
Could sirtuin activities modify ALS onset and progression?
Tang, B. L. (2017) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-016-0452-2 · Cited by 24
Metadata
- Authors
- Mazzini, L., Vescovi, A., Cantello, R., Gelati, M., & Vercelli, A.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa UK Limited
- Published
- 2016-01-09
- Volume
- 16
- Issue
- 2
- Pages
- 187-199
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2194947581
- Cited by
- 36
- References
- 8
- FWCI
- 2.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Stem cells therapy for ALS. https://app.cochat.ai/papers/10.1517/14712598.2016.1116516
- The paper
- Mazzini, L., Vescovi, A., Cantello, R., Gelati, M., & Vercelli, A. (2016). Stem cells therapy for ALS. Expert Opinion on Biological Therapy. https://doi.org/10.1517/14712598.2016.1116516
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.